AKBA Akebia Therapeutics Inc.

$AKBA now that the 30 day consecutive over $1 rule has been reset, it is interesting that volume was just 3 mm today. Seems almost like all the hedge funds "in the know" already loaded up and have finished. They too are awaiting for wonderful Vocal Vafseo trial results to be released to us retail investors. Crazy manipulation that has been going on for years in this stock. Smh. Let us finally get our day in the sun and allow akba to grow into the next big pharma like Amgen did. Here is hoping for that. We have been patiently waiting way too long for akba to realize its potential.

$AKBA volume has nearly vanished almost like the MMs have finished loading the boat and waiting for imminent Vocal trial news to be released. I still estimate that gets released this Thurs 9/17. We shall see though. All signs point to Vocal results being very good for Vafseo vs inferior ESAs. Another honor badge for Vafseo I guess. This may start the Davita mass adoption of Vafseo too, the top down approach we all have been waiting for. Glta. Wont be long till stock price moves exponentially higher from these lows.

$AKBA Just two more weeks till q3 2026 comes to a close. Q4 is when Vocal results are set to come out and we know Friday Oct 2nd is when 2026 ASN abstracts are revealed to the public, even for late breaking abstracts (LBA) at least the titles will be revealed in two weeks. On time abstracts will have full details in two weeks. So shorts will play their games but much sooner than later Vafseo will be SOC for DD anemia care, meaning at least $500-600 mm a year in revenue and that is WITHOUT Fresenius, now imagine that number with them on board too. ESA days are numbered. Only thing that we should be worried about is a competitive buyout offer of $25-30 per akba share which may get though. Any low ball offer of $7-10 will be squashed immediately with a CT order but the competitive BO may get though. Also any Low ball BO offer jumps akba's stock price to that higher ($7-10) LEVEL too, automatically. So either way we will be fine very soon. So keep ur heads up. Our time is near.

$AKBA GM and Happy Friday! August Symphony/Bloomberg for Vafseo: IWAC $1.39M vs $1.48M in July, units 35.5k vs 38.5k. Looks soft. That feed is only the visible wholesale slice as most in-clinic USRC/DaVita bottles never show up there. Price per unit was basically flat, so this isn’t a new rebate cliff in that channel. It can also look worse if TIW is ramping, ie fewer bottles per patient than daily packs. Could be Labor Day and/or inventory too. Need Q3 patient count to know if adds stalled or if the screen is just blind + mix. TIW in the chair can print fewer “units” even with the same patients, because you are not sending a 30-count daily bottle home. Same people, fewer packs in the data. TIW + flat 10.5k is “mix, not growth.” TIW + 12k+ patients is what I am hoping. Have a great weekend! (Units to follow)

$AKBA THIS IS NOT HARD - (1)Nov. 10, ’25, Akebia announced that it expects Davita’s operational pilot (VOCAL) to complete in Nov. ’26 at which point Vafseo is to be widely available to 275K patients; (2)June ’26, in the very beginning, Davita began a village-wide rollout of Vafseo 3Xs weekly dosing protocol; (3)June 30, ’26, Akebia & U.S. Renal Care stopped Phase 4 Vafseo trial after analysis demonstrated SUPERIORITY over ESAs. OVERWHELMING statistical evidence of improved safety outcomes; (4)Aug. 12, ’26, VOCAL study ”completed … data review underway.” (SPZCO, TipRanks). STANDARD OF CARE INEVITABILITY? Good luck ☘️ to us all.

$AKBA Holding 2,527,717 shares long. Looking forward to VOCAL trial results, confirmation of Davita adoption and rollout, affirmation of Fresenius’ protocol, extension of TDAPA, pipeline news, parabolic price rise, and inducement grants. Good luck ☘️ to honest investors.

$AKBA Anyone looking forward to Bloomberg data tomorrow? I'd be down to skip so we can try and muster up some good weekend vibes lol. I'll take 1.6MM+ IWAC and would love for it to be 1.9M+. See y'all in the morning.

$AKBA we are investing in a drug that works, we dont care about the chart. If you really trust what they are doing even if the management is not the best, we will win in the long run. Patience is key, dont look too much the board because bears will always post bullshit and that’s a good sign. Be greedy when others are fearful✌️

$AKBA NASDAQ Composite, bloody red; NYSE Composite, bloody red; DOW JONES Industrial Average, bloody red. Akebia Therapeutics, emerald green -

$AKBA The news today (first-patient dosing) is a big milestone for Akebia - adding a biologic modality in addition to small molecules. The biologic modality brings structurally stronger, longer exclusivity (12-yr BPCIA data exclusivity + weak/slow biosimilar threat vs. fast small-molecule generics) and rare-disease premium pricing (vs. bundle-compressed Vafseo economics). Much of the initial lift was inherited via the Q32 acquisition (de-risked clinical-stage biologic with CMC done), so Akebia's near-term burden is managing an inherited program, not building capability from scratch. The bigger future lift is commercial-scale manufacturing and a new specialty commercial infrastructure if ebribafusp succeeds. The upside: biologics offer stronger exclusivity and better unit economics — which is exactly why the modality shift should support the rare-disease-platform re-rating story.

$AKBA its a busy month for akebia’s MSLs doing Vafseo dinner presentations during the nephrology nurses week . Steak is on menu.

$AKBA It was brought to my attention that there's another clone of mine. These accounts block who they're cloning so I don't know if my report was valid or not. https://stocktwits.com/BidzlLL Feel free to report at your leisure to help prevent anyone from falling for these scammers! Thank you all!

$AKBA Remember after earnings when Steve The Bull said,” Sorry guys, this is going to $.50-.60.” And when someone asked why he thought that he said, “just cause.” Remember that the next time one of these “experts” pulls some abitrary numbers out their arse. Believe in what you own. Stick to your convictions. Ignore the noise.

$AKBA NCT07429006, update posted Sept 9: SAD: five dose cohorts → four MAD: three dose cohorts → one Enrollment: 70 → 44 (−37%) Primary completion: Oct 2026 → Dec 2026 SAD, RBC and reticulocyte count: Day 2 → Days 2, 8 and 13 MAD, RBC and reticulocyte count: Days 4 and 8 → Days 4, 8, 14 and 21

$AKBA Nice find. If KCAPA is going to pass HOUSE vote this is going to put additional pressure to CMS:

$AKBA Interesting period, waiting for vocal. Should take short activity down. Low volume but without that pressure maybe we can rise. All funds bought under $1 imho with all that volume. L F G ! 👍🙏

$AKBA OK, now I'm glad I bought 2K shares at the open, let's hope it holds or even better takes off finally.

$AKBA This treatment may get fast track! Mark it!! 10:13 AM EDT, 09/14/2026 (MT Newswires) -- Akebia Therapeutics (AKBA) said Monday it has dosed the first patient in an open-label Phase 2 basket trial testing ebribafusp as a treatment for rare complement-mediated kidney diseases. The mid-stage study will enroll up to 30 patients for 26 weeks of weekly subcutaneous dosing to primarily evaluate adverse events, alongside secondary renal function metrics, the company said. The biopharmaceutical firm expects to report initial data in 2027 for the investigational fusion protein, which inhibits complement activation in tissues without inhibiting the complement system in the blood, Akebia added.

$AKBA recent data is supporting and making Akebia's people less shy talking about TIW dosage. Great!

$AKBA The "short any news approach" with recycling shares through dark pools and wash trades and partial covering via whoever they trick to sell in the open market. Tomorrow is the KCAPA hearing. It will influence CMS.